side effects glp 1 receptor agonists Frontiers Table 2 from Optimizing Outcomes
Description
Canadian Journal of Physiology and Pharmacology
received honoraria for speaking at meetings from Novartis, Sanofi-Aventis, Lilly, AstraZeneca, Boehringer Ingelheim, and NovoNordisk
Willard, F.S., et al
Generalizations such as one patient out of 10 had developed aspiration should not have been assumed as a 10% risk of aspiration for patients on GLP-1 RAs exists due to the sample size, for example
Stimulation of gluconeogenesis by long chain fatty acids and glucagon
